semaglutide prediabetes progression to diabetes step trial Reversion normoglycemia with tirzepatide vs in participants with obesity and prediabetes: a post hoc analysis of SURMOUNT-5 | Journal of Endocrinological Investigation Delaying Type 1 Diabetes Progression

Sleep problems are not currently recognised as one of the main retatrutide side effects

The strongest data we have come from standard dosing : In STEP 1, once-weekly semaglutide 2.4 mg plus lifestyle support produced clinically meaningful average weight loss and improvements in cardiometabolic risk factors

They have been reported to reduce symptoms of angina and peripheral vascular disease, and they may improve outcomes for people with serious heart conditions, such as coronary heart disease or heart failure [5]

2021 Wegovy (semaglutide) receives FDA approval for chronic weight management in people with a weight-related condition like high blood pressure, high cholesterol or Type 2 diabetes

It names active eating disorders, severe gastrointestinal motility disorders, severe kidney disease with an eGFR under 30, and concurrent use of medications that increase GLP-1 effect unpredictably

it is about improving body composition, maintaining strength, and protecting long-term vitality